Janssen-Cilag International N.V. submitted an MAA to EMA for bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Bedaquiline is a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase.
I have written earlier that anti-infectious drugs are not very profitable for Big Pharma (see also here), therefore this new antibiotic is very welcomed.
No comments:
Post a Comment